Oklo stock rose 1.21% pre-market after DOE startup authorization news.
DOE cleared Groves reactor for fuel loading, testing, and operations.
Groves supports domestic isotope production for healthcare and research.
Privately funded reactor establishes a repeatable commercial deployment model.
Groves experience strengthens Oklo’s future advanced nuclear project pipeline.
Oklo Inc. (OKLO) shares closed at $44.00, down 1.12%, before rising 1.21% to $44.54 in pre-market trading. The recovery followed the company’s announcement that it received startup authorization for its Groves Isotope Test Reactor. The approval allows fuel loading, startup testing, and reactor operations under the U.S. Department of Energy Reactor Pilot Program.
The U.S. Department of Energy granted startup authorization after completing its review under the Reactor Pilot Program. As a result, Oklo can begin fuel loading, startup testing, and reactor operations at the Groves Isotope Test Reactor. The authorization completes the federal approval process for the facility.
Groves serves as a low-power test reactor supporting reactor design, operations and future isotope production. The project supports domestic isotope manufacturing for healthcare, scientific research, industrial applications, space missions, and national security. The facility also provides operating experience for future commercial deployments.
Oklo financed the project privately and constructed the reactor on privately owned land. The company completed civil construction and installed full-scale systems using commercially sourced or internally manufactured components. Consequently, the project demonstrated a repeatable deployment model without relying on an existing national laboratory framework.
The Department of Energy completed a readiness review before granting startup authorization. The review confirmed engineering readiness, operational preparation, personnel training, and compliance with approved safety requirements. It also verified that safety systems and facility equipment matched the approved reactor design.
Oklo developed its operational programs internally throughout the project. These programs included quality assurance, security, environmental protection, health and safety, and operating procedures. Therefore, the company established operational capabilities that can support additional reactor projects.
Company leadership stated that Groves progressed from a greenfield site to substantial completion in record time for a privately funded reactor. The project demonstrated commercial procurement, full-scale construction, and integrated operational development within one facility. Furthermore, the experience created standardized processes for future deployments.
The Reactor Pilot Program allowed construction and organizational readiness activities while the Department of Energy completed regulatory reviews. This approach enabled project development without reducing federal safety requirements. Oklo advanced construction and operational preparation in parallel with government oversight.
Future Oklo facilities will use the engineering systems, qualified suppliers, and operating programs established through Groves. The company expects these standardized processes to reduce execution complexity across future deployments. In addition, the operating experience gained at Groves supports expansion across multiple business activities.
The announcement arrived as Oklo shares recovered from the previous trading session. The stock climbed to $44.54 in pre-market trading after closing at $44.00, reflecting renewed market interest following the regulatory milestone. The authorization also advances Oklo’s broader strategy to expand advanced nuclear technology and domestic isotope production in the United States.
The post Oklo (OKLO) Stock: Rebounds After Reactor Startup Authorization Advances Nuclear Expansion appeared first on CoinCentral.
